FDA Priority Review For Some Generics Urged To Address 'Market Failure'

Senate Aging Committee hearing addresses generic drug priority reviews at FDA, compounding and publicizing a “watch list” of off-patent drugs with no competition as ways of deterring dramatic price increases for such products.

FDA should be able to establish a priority review process for generic drugs where there is minimal price competition for an off-patent drug, Gerard Anderson, professor of health policy and management at Johns Hopkins University, told the Senate Special Committee on Aging at a Dec. 9 hearing.

Such an approach would help to deter drug firms like Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc....

More from United States

More from North America